RPG Life Sciences — 360° view

RPG Life Sciences, a company in the Pharmaceuticals industry, reported revenue of ₹212 crore and net profit of ₹28 crore for the September 2026 quarter.

RPG Life Sciences (NSE: RPGLIFE) closed at ₹2,540.90 on 20 Nov 2026, up 14.2% over the past year. Its market capitalisation is ₹4,202 crore and it trades at 36.6 times earnings.

Share price
₹2,540.90 (20 Nov 2026)
Market cap
₹4,202 Cr (20 Nov 2026)
P/E
36.61 (20 Nov 2026)
Revenue
₹212 Cr (September 2026 quarter)
Net profit
₹28 Cr (September 2026 quarter)
ROCE
25.7% (FY26)
ROE
19.3% (FY26)
Book value
₹416 (FY26)
Dividend yield
0.94% (last 12 months to 20 Nov 2026)
52-week high / low
₹3,127.80 / ₹1,733.00 (20 Nov 2026)
1-year return
14.2% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: RPGLIFE

Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.